The effect of sorafenib treatment on the diabetic status of patients with renal cell or hepatocellular carcinoma.
OBJECTIVE
To evaluate the effect of sorafenib on the glucose tolerance and diabetic status of patients with metastatic renal cell carcinoma (RCC) or advanced hepatocellular carcinoma (HCC).


METHODS
Eighty patients with metastatic RCC or advanced HCC received 400 mg sorafenib twice daily for an average of approximately 8 and 5 months, respectively; 22 had diabetes mellitus and three had prediabetes.


RESULTS
One of 55 nondiabetic patients, and one of three patients with impaired fasting glucose or impaired glucose tolerance developed diabetes mellitus, one of 12 patients on oral antihyperglycemic agents switched to insulin and no patient treated with insulin needed to increase their dose.


CONCLUSIONS
Sorafenib has the potential to be a feasible and safe treatment option for patients with advanced HCC or metastatic RCC and comorbid diabetes mellitus or prediabetes.
Medical Oncology, IRCCS San Matteo University Hospital Foundation, Piazzale Camillo Golgi 19, 27100 Pavia, Italy.
Ilaria
I
Imarisio
Chiara
C
Paglino
Carlo
C
Ganini
Luigi
L
Magnani
Riccardo
R
Caccialanza
Camillo
C
Porta
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001557:Benzenesulfonates / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000453:epidemiology; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology; D015897:Comorbidity; D003920:Diabetes Mellitus / Q000453:epidemiology*; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000453:epidemiology; D009362:Neoplasm Metastasis; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000077157:Sorafenib; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib